Clinical Trials Directory

Trials / Unknown

UnknownNCT05054075

Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19

Methodological Design for Evaluating the Immune Capacity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Human Infection: Intelligent Medicine Integration.

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
Universidade do Porto · Academic / Other
Sex
All
Age
14 Years
Healthy volunteers
Accepted

Summary

The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an integrative diagnosis by a computational Mora®Nova apparatus to access the basal and experimental human physiological parameters.

Detailed description

A deep and consistent study will be developed with an increase in the human sampling for better understanding the intervention efficacy of this intelligence medicine integrator, the Mora® Nova method. These in silico experiments when associated with the bioresonance frequencies from stimulated hemolymph compounds of the freshwater bivalve A. cygnea, may lead us to expect high plasticity and immunological potential. Obviously, additional in vitro studies in future, with adequate culture cell lineages in different conditions and with bioresonance treatment by Mora® Nova method, should also be accomplished with hemolymph/plasma interference to confirm the pertinence, and the real efficacy on SARS / COVID-19 infection as well as to clarify the respective biological mechanisms. In addition, to analyze and evaluate any specific bioactive compound from the induced hemolymph condition needs molecular experiments which can give deep structural information concerning any efficient molecule against the SARS / COVID-19 virus lineage and respective mutants. Effectively, according to current scientific opinion, the virus mutation phenomenon leads to great and problematic difficulty for maintaining the collective and human global immunization. In this case, the present Mora methodology offers a very functional, dynamic, and efficient process when combined with a biological model, as the bivalve A. cygnea, with high plasticity and eventual molecular reconstructive adaptation. This Mora procedure can extend to other immune-depressive diseases namely cancer, rheumatoid arthritis, and neurodegenerative diseases combining with respective stimulated bivalve fluids. It suggests opening a promising future perspective when applied to large human sampling as well as with in vitro cellular assays. In addition, to explore this research with in vitro cell cultures and to do the characterization and the effects from bio-compounds on similar diseases is our close objective.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMarine liquid and fluidsMarine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)
BIOLOGICALImpregnationSARS / COVID-19 fluid/liquid - impregnation
BIOLOGICALIncubationSARS / COVID-19 fluid-bivalve-incubation
BIOLOGICALManipulationBivalve Manipulation - Stress inducing
BIOLOGICALRefrigerationRefrigerated fluid to check for maintained response

Timeline

Start date
2021-10-01
Primary completion
2022-10-01
Completion
2022-11-01
First posted
2021-09-23
Last updated
2022-04-15

Locations

2 sites across 1 country: Portugal

Source: ClinicalTrials.gov record NCT05054075. Inclusion in this directory is not an endorsement.